Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Codexis, Inc.NASDAQ: CDXS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $9.67M fell 21.7% year over year, behind the -19.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 9.3% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.

Context

  • Selling, general & admin amounted to 66.9% of revenue in FY2025, down 26.0 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $47.28M (+0.4%) for the fiscal year ending Dec 2026, a step up from the -14.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.67M-9.3% QoQ
Last fiscal yearDec 2025
$47.07M-14.6% YoY
LTMMar 2026
$43.75M-19.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.7%-27.4%-5.6 pp
1 year-14.6%+0.4%+15.1 pp
3-year CAGR-3.4%+14.8%+18.2 pp
5-year CAGR+18.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
47.07M USD
Year-over-year change
-14.6%
4-year CAGR
-1.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.9% is the 9th highest of 10, against a peer median of -7.8%.
  • Selling, general & admin amounts to 56.0% of revenue for CDXS, versus a peer median of 264.3%.
CDXS Competitors
Selling, General & Admin for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$74.78M USD+14.7%+12.5%133.9%
CDXSCodexis, Inc.LTM Mar 2026$43.75M USD-19.9%-3.4%56.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M USD-16.4%-5.4%98.7%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$31.65M USD-26.4%-17.7%91.6%
OABIOmniAb, Inc.LTM Mar 2026$26.47M USD-12.7%+5.5%91.6%
TARAProtara Therapeutics, Inc.LTM Mar 2026$23.01M USD+25.6%+1.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$19.01M USD-17.8%-9.7%599.8%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.81M USD+22.1%-7.6%914.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$12.62M USD-4.8%+18.6%426.6%
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
Peer median (excluding CDXS) —-7.8%-5.4%264.3%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.